MMRGlobal, Inc. (fka MMRF)

[Tulaz1]

Sept. 13, 2010

MMRGlobal, Inc. (OTCBB: MMRF) (www.mymedicalrecords.com) today revealed that according to an expert retained by the Company, the relevant human tissue samples that are part of its biotech assets may have a value of at least $1.376 million. However, when
combined with clinical data from the Company's vaccine research into the causes and potential treatment of B-Cell Non-Hodgkin's Lymphoma, including data from patient follow-ups and the existence of whole blood or serums, if any, the value could be inestimable. MMRGlobal has retained scientific experts and advisors on behalf of its efforts to protect a portion of the Company's intellectual property and related technology claims pertaining to the Lymphoma Research Foundation. The Company acquired these assets through its reverse merger with
Favrille, Inc., a biopharmaceutical company, in January 2009. Favrille was previously based in San Diego.

On April 14, 2010, MMRGlobal announced the existence of intellectual property in the form of approximately 150 patient samples collected during the Company'spre-merger Favrille vaccine trials. Through May of 2008, pre-merger Favrille had spent more than $140 million on the creation and development of intellectual
property, which includes clinical trials data, patient samples, patents and other assets. The Company is working towards entering into licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of the assets.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54326219
=================================================================
On December 21, 2010, MMRGlobal, Inc., a Delaware corporation (the "Company"), entered into a Non-Exclusive License Agreement (the "Agreement") with Celgene Corporation ("Celgene").

Pursuant to the terms of the Agreement, the Company will license to Celgene, on a non-exclusive basis, the use of the Company's clinical and scientific data relating to targeted immunotherapies for cancer and other disease treatments to stimulate a patient's immune response and certain other confidential information.

In consideration for the rights granted under the Agreement, Celgene will pay the Company certain upfront fees and, upon achievement of development milestones, milestone payments in the aggregate amount of approximately $13 million plus any expenses. The Agreement contains customary provisions, as to the term of the Agreement, representations, warranties, and indemnities by each of the Company and Celgene.
http://sec.gov/Archives/edgar/data/1285701/000113626110000355/body8k.htm

=================================================================